• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

INNATE PHARMA (IPH)

INNATE PHARMA
Sell: €1.346|Buy: €1.44|Change: 0.06 (-4.26%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Address

117, Avenue de Luminy - BP 30191
Marseille
FRA
13 009

Telephone

+33 430303087

Website

https://www.innate-pharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Innate Pharma SA Annual Report for 20262027-04-01T00:00:00
Innate Pharma SA Fourth Quarter Earnings Conference Call for 20262027-03-26T09:00:00
Innate Pharma SA Fourth Quarter Earnings Results for 20262027-03-26T00:00:00
Innate Pharma SA Third Quarter Earnings Result for 20262026-11-05T00:00:00
Innate Pharma SA Third Quarter Earnings Conference Call for 20262026-11-05T00:00:00
Innate Pharma SA Second Quarter Earnings Result for 20262026-09-17T00:00:00
Innate Pharma SA Second Quarter Earnings Conference Call for 20262026-09-17T00:00:00
Innate Pharma SA Annual General Meeting for 20262026-05-21T00:00:00
Innate Pharma SA First Quarter Earnings Result for 20262026-05-13T00:00:00
Innate Pharma SA First Quarter Earnings Conference Call for 20262026-05-13T00:00:00
Innate Pharma SA Annual Report for 20252026-04-01T00:00:00

Previous key dates

NameKey Date
Innate Pharma SA Annual Report for 20252026-04-01T00:00:00
Innate Pharma SA Fourth Quarter Earnings Conference Call for 20252026-03-26T09:00:00
Innate Pharma SA Fourth Quarter Earnings Result for 20252026-03-26T00:00:00
Leerink Partners Global Healthcare Conference2026-03-09T15:40:00
Jefferies Global Healthcare Conference2025-11-17T09:30:00
Innate Pharma SA Third Quarter Earnings Conference Call for 20252025-11-13T08:00:00
Innate Pharma SA Third Quarter Earnings Result for 20252025-11-13T00:00:00
Innate Pharma In-Person and Virtual Lacutamab KOL Event: Clinical Perspectives & Market Outlook2025-10-28T08:00:00
Innate Pharma SA Second Quarter Earnings Conference Call for 20252025-09-17T08:00:00
Innate Pharma SA Second Quarter Earnings Result for 20252025-09-17T00:00:00
Innate Pharma SA Annual General Meeting for 20252025-05-22T10:30:00
Innate Pharma SA First Quarter Earnings Conference Call for 20252025-05-13T14:00:00
Innate Pharma SA First Quarter Earnings Result for 20252025-05-13T00:00:00
Innate Pharma SA Annual Report for 20242025-05-02T00:00:00
Stifel's 2025 Virtual Targeted Oncology Forum2025-04-09T12:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.